Stage B, A Pre-cursor to Heart Failure, Part II, An Issue of Heart Failure Clinics
Published on 28. April 2012
704 pages
978-1-4557-4406-0 (ISBN)
Description
In the joint American College of Cardiology /American Heart Association classification system, Stage B heart failure refers to patients with structural heart disease but no symptoms of heart failure. Preventing progression of heart failure in Stage B patients is a central concern to heart failure specialists, so two issues have been devoted to this topic. Part II focuses on screening to identify patients with Stage B HF and monitoring and therapeutic approaches to patients with a diagnosis of Stage B HF.
More details
Other editions
Additional editions
Jay N. Cohn | Gary S. Francis
Stage B, A Pre-cursor to Heart Failure, Part II, An Issue of Heart Failure Clinics: Volume 8-2
Volume 8-2
Book
04/2012
Saunders
€100.50
Shipment within 10-15 days
Content
- Front Cover
- Heart Failure Clinics
- Copyright Page
- Table of Contents
- Contributors
- Heart Failure Clinics
- Editorial: Reducing the Burden of Stage B Heart Failure and the Global Pandemic of Cardiovascular Disease: Time to Go to War with the "Barefoot" Troops!
- REFERENCES
- Preface: Stage B, A Precursor of Heart Failure, Part I I
- Chapter 1. Clinical Monitoring of Stage B Heart Failure: Echocardiography
- WHY SCREEN FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION WITH ECHOCARDIOGRAPHY?
- ECHOCARDIOGRAPHIC ABNORMALITIES INCLUDED IN THE DEFINITION OF STAGE B HEART FAILURE
- WHAT ARE THE IMPORTANT VARIABLES TO ASSESS IN THE ECHOCARDIOGRAPHIC EVALUATION?
- ROLE OF ECHOCARDIOGRAPHY IN SELECTED POPULATIONS
- COST EFFECTIVENESS AND HANDHELD ECHOCARDIOGRAPHY
- SUMMARY
- REFERENCES
- Chapter 2. Cardiac Magnetic Resonance Imaging for Stage B Heart Failure
- CARDIAC MAGNETIC RESONANCE IMAGING FOR HEART FAILURE: TECHNICAL CONSIDERATIONS
- ASSESSMENT OF LEFT VENTRICULAR FUNCTION
- DETERMINING CAUSE
- FURTHER ASSESSMENTS IN ISCHEMIC CARDIOMYOPATHY
- RISK STRATIFICATION AND PROGNOSIS
- FUTURE DIRECTIONS
- SUMMARY
- REFERENCES
- Chapter 3. Radionuclide Imaging in Stage B Heart Failure
- STAGE B HEART FAILURE: IMPORTANCE OF RECOGNITION
- ROLE OF RADIONUCLIDE IMAGING IN STAGE B HEART FAILURE
- SUMMARY
- REFERENCES
- Chapter 4. Biomarkers
- BIOMARKERS OF NEUROHORMONAL ACTIVATION
- NATRIURETIC PEPTIDES
- BIOMARKERS OF MYOCYTE INJURY
- BIOMARKERS OF EXTRACELLULAR MATRIX REMODELING
- BIOMARKERS OF INFLAMMATION
- BIOMARKERS OF OXIDATIVE STRESS
- NEW BIOMARKERS IN HEART FAILURE
- SUMMARY
- REFERENCES
- Chapter 5. The Role of Renin Angiotensin System Intervention in Stage B Heart Failure
- THE ROLE OF RAAS ACTIVATION IN STAGE B HF
- RAAS INTERVENTIONS IN STAGE B HF
- SUMMARY AND FUTURE DIRECTIONS
- REFERENCES
- Chapter 6. b-Blockers in Stage B: A Precursor of Heart Failure
- ACTIVATION OF NEUROHORMONES IN HF
- HALLMARKS OF HF
- ADVERSE EFFECTS OF NEUROHORMONAL SYSTEMS IN HF
- DIRECT CARDIOTOXIC EFFECTS OF NEUROHORMONES
- THE RATIONALE FOR b-ADRENERGIC BLOCKING THERAPY IN STAGE B, A PRECURSOR OF HF
- CLINICAL TRIALS OF b-ADRENERGIC BLOCKERS IN PATIENTS WITH HF
- ROLE OF BRADYCARDIA IN THE TREATMENT OF HEART FAILURE
- SUMMARY
- REFERENCES
- Chapter 7. The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology/American Heart Association Stage B Heart Failure
- RATIONALE FOR THE USE OF MRAS IN PATIENTS WITH STAGE B HF
- MRAS IN PATIENTS WITH HYPERTENSIVE HEART DISEASE
- ROLE OF MRAS ON IMPORTANT COMORBID CONDITIONS TRIGGERING THE DEVELOPMENT OF MANIFEST HF IN STAGE B
- THE ROLE OF ACE-I AND/OR ARB IN PREVENTING THE PRODUCTION OF ALDOSTERONE FROM THE ADRENAL GLAND
- THE CHOICE OF AN MRA IN PATIENTS WITH STAGE B HF
- LIMITATIONS TO THE USE OF AN MRA IN PATIENTS WITH STAGE B HF
- SUMMARY
- REFERENCES
- Chapter 8. Nitric Oxide Modulation as a Therapeutic Strategy in Heart Failure
- GENERATION OF NITRIC OXIDE AND NITRIC OXIDE EFFECTOR PATHWAYS
- NITRIC OXIDE AND NITROSO-REDOX BALANCE IN HEART FAILURE
- NITRIC OXIDE AS A THERAPEUTIC TARGET IN HEART FAILURE
- NITRIC OXIDE DONORS
- SOLUBLE GUANYLYL CYCLASE AS A TARGET FOR TREATMENT OF HEART FAILURE
- PDE-5 INHIBITION IN SYSTOLIC HEART FAILURE
- SUMMARY
- REFERENCES
- Stage B Heart Failure: Rationale for Screening
- WHAT IS THE BURDEN OF SUFFERING ASSOCIATED WITH HEART FAILURE?
- WHICH INDIVIDUALS ARE AT RISK OF DEVELOPING SYMPTOMATIC HEART FAILURE?
- WHAT IS THE RISK ASSOCIATED WITH STAGE B HEART FAILURE?
- WILL EARLY DETECTION AND TREATMENT OF STAGE B HEART FAILURE IMPROVE CLINICAL OUTCOMES?
- HOW SHOULD ONE EVALUATE A SCREENING STRATEGY?
- THE CASE FOR SCREENING FOR ASYMPTOMATIC LVSD
- SUMMARY
- REFERENCES
- Chapter 9. Strategies to Screen for Stage B as a Heart Failure Prevention Intervention
- PREVALENCE AND NATURAL HISTORY OF STAGE B HF AND IMPLICATIONS FOR SCREENING
- CRITERIA NEEDED TO JUSTIFY SCREENING PROGRAMS
- POTENTIAL SCREENING STRATEGIES
- SUMMARY
- REFERENCES
- Index
